phase ii trial of cabozantinib for patients with hcc previously treated with io
Published 1 year ago • 38 plays • Length 2:58Download video MP4
Download video MP3
Similar videos
-
1:36
cabozantinib in patients with hcc refractory to checkpoint inhibitors
-
0:54
phase ib/ii trial of 177lu-girentuximab with cabozantinib and nivolumab in clear cell rcc
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
0:48
phase i/ii trial of adapt-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors
-
3:54
papmet2: cabozantinib with or without atezolizumab in prcc
-
0:53
carina: cabozantinib post first-line immune-oncology cpi-containing combination in arcc
-
2:25
keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma
-
1:20
promising results of cabozantinib plus nivolumab in non-clear cell rcc
-
2:15
phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
-
1:07
recent advancements for the treatment of liver cancer
-
0:52
next steps for cabozantinib plus durvalumab in gi cancer
-
8:40
advanced hcc: celestial trial
-
1:24
ahmed kaseb, md, on combining cabozantinib with checkpoint inhibitors for treatment of hcc
-
15:03
outcomes for immunosuppressed vs non-immunosuppressed cancer patients with covid-19 treated with io
-
1:40
phase iii meteor trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinoma
-
6:39
emerging second-line therapies in hcc
-
3:24
cabeyond: cabozantinib beyond pd and survival outcomes in mrcc
-
2:33
celestial trial: second-line cabozantinib’s value in hcc
-
3:22
daneng li, md, considers the role of cabozantinib and other tkis as hcc patients progress on i-o